Given the high expression level of SHARP1 comparable to those of pivotal oncogenic target genes, HOXA9 and MEIS1, in MLL-AF6 AML patients, we hypothesized that SHARP1 plays an oncogenic role in MLL-AF6 AML cells. The gene discussed is KMT2A; the disease is acute myeloid leukemia.